Pre-emptive ganciclovir preferred for CMV disease after kidney transplant

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.273, 2000-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pre-emptive ganciclovir preferred after renal transplantation

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach

By Gerna Giuseppe Baldanti Fausto Lilleri Daniele

Future Virology, Vol. 4, Iss. 2, 2009-03 ,pp. : 155-164

Future Medicine

Access to resources Recommend Favorite

Preemptive vs prophylactic therapy for CMV disease prevention

Inpharma, Vol. 1, Iss. 1630-1631, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A 3-Year Follow-Up of Pre-Emptive vs Deferred Treatment of Cytomegalovirus Disease in Renal Transplantation

By Brennan D.C.

Clinical Drug Investigation, Vol. 19, Iss. 5, 2000-05 ,pp. : 367-374

Adis International

Access to resources Recommend Favorite

Prophylactic antivirals prevent CMV disease in transplant recipients

Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite